Showing 1591-1600 of 1774 results for "".
- Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinitehttps://modernod.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/Glaukos announced the completion of patient enrollment in its FDA Investigational Device Exemption (IDE) trial for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure to reduce elevated IOP in refractory glaucoma patients. I
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- AlpineInvestors to Make Strategic Growth Investments in Ohio Eye Care Businesseshttps://modernod.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/Private equity firm Alpine Investors has invested in Ohio-based eye care business, Northeast Ohio Eye Surgeons (NEOES), including its subsidiary business, Ohio Eye Care Consultants (OECC). The two companies will together form a new ophthalmology platform for Alpine, and will continue to operate i
- Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honorhttps://modernod.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/Avellino Labs announced the company’s founder, chairman, and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Honor. In addition, Mr. Lee has been appointed to the World Economic Forum’s Precision Medicine Council. One of the nation’s most prestigious awards, the Ellis I
- Alimera Sciences Appoints Samer Kaba, MD, as Chief Medical Officerhttps://modernod.com/news/alimera-sciences-appoints-samer-kaba-md-as-chief-medical-officer/2476464/Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019. “I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspect
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i